Managers

DayTwo pulls in $31 mln Series B

Israel-based DayTwo, a microbiome human discovery platform, has secured $31 million in Series B financing. The lead investors were aMoon and Ofek Ventures.

Healthy Ventures to raise $50 mln for sophomore fund

Healthy Ventures is seeking to raise $50 million for its second fund, according to an SEC filing. The San Francisco-based venture firm targets infrastructure software in healthcare.

Healthcare services provider Remedy scores $10 mln Series A

Austin-based Remedy, a provider of healthcare services, has raised $10 million in Series A financing. Santé Ventures led the round.

Encoded Therapeutics inks $104 mln Series C

South San Francisco-based Encoded Therapeutics Inc, a precision gene therapy company, has secured $104 million in Series C funding. The investors included Venrock, ARCH Venture Partners, Matrix Capital Management, Illumina Ventures and Altitude Life Science Ventures.

TissueTech snags $82.25 mln

Miami-based TissueTech Inc, a provider of therapeutic solutions for the ocular surface, wounds, surgery and other applications, has raised $82.25 million in financing. EW Healthcare Partners led the round.

Miraki’s Velis on investing in lab technology and reserving for today’s larger rounds

Fund Performance: Insight, NEA and Oak HC/FT are big winners in LACERS portfolio

XVC is seeking $265 mil towards second venture fund

Supreme Cannabis unveils European investment platform

Supreme Cannabis Co Inc said it will launch a new platform for investing in Europe's cannabidiol (CBD) health and wellness sector. Supreme Heights will make strategic investments in and lend support to U.K. and European health and wellness businesses with focused brands and CBD offerings, including vaporizers, edibles and beverages, topicals and ancillary services. Based in London, Supreme Heights will be led by CEO Patrick Morton, co-founder of Cannabis Invest UK. Toronto-based Supreme Cannabis is a provider of cannabis products for commercial and medical use.

InterVene amasses $15 mln Series B

South San Francisco-based InterVene, a provider of a catheter-based solution for deep vein reflux, has raised $15 million in Series B financing. The lead investor was 3x5 Partners.